Design of an Optimized Wilms’ Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo
Tumor antigen–encoding mRNA for dendritic cell (DC)-based vaccination has gained increasing popularity in recent years. Within this context, two main strategies have entered the clinical trial stage: the use of mRNA for ex vivo antigen loading of DCs and the direct application of mRNA as a source of...
Main Authors: | Daphné Benteyn, Sébastien Anguille, Sandra Van Lint, Carlo Heirman, An MT Van Nuffel, Jurgen Corthals, Sebastian Ochsenreither, Wim Waelput, Katrien Van Beneden, Karine Breckpot, Viggo Van Tendeloo, Kris Thielemans, Aude Bonehill |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2013-01-01
|
Series: | Molecular Therapy: Nucleic Acids |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253116301901 |
Similar Items
-
Characterization of CD8+ T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)
by: Daphné Benteyn, et al.
Published: (2013-01-01) -
Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination
by: Ochsenreither Sebastian, et al.
Published: (2010-01-01) -
The Wilms' tumor (WT1) gene: Methods and protocols
by: Suraksha Agrawal
Published: (2018-01-01) -
An investigation of mouse Basp1 and Wt1-AS, genes involved in the regulation of the Wilms' Tumour suppressor protein, Wt1
by: Allsop, Joanne
Published: (2008) -
The role of the Wilms tumour gene WT1 in leukaemia and familial Wilms tumour
by: King-Underwood, Linda
Published: (1998)